Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275799 | 0.92 | HRH4 (0.45) | HRH4LRRK2NOX1ITGB3ITGAV | |
| SCHEMBL1276355 | 0.92 | SCN9A (0.47) | HRH4LRRK2NOX1SCN9ACCNT1 | |
| SCHEMBL1276322 | 0.87 | HRH4 (0.44) | HRH4SCN9APAK1CCNT1CCNK | |
| SCHEMBL1276116 | 0.84 | HRH4 (0.51) | HRH4LRRK2NOX1ITGB2ICAM1 | |
| SCHEMBL12805202 | 0.84 | NOX1 (0.42) | HRH4LRRK2NOX1EGFRHTR1A | |
| SCHEMBL30132827 | 0.84 | HRH4 (0.46) | HRH4LRRK2NOX1EGFR | |
| SCHEMBL1276103 | 0.84 | HRH4 (0.46) | HRH4LRRK2NOX1EGFR | |
| SCHEMBL1276028 | 0.84 | KMT2A (0.51) | HRH4LRRK2NOX1HTR1ADRD2 | |
| SCHEMBL1275419 | 0.82 | JAK3 (0.48) | HRH4EGFR | |
| SCHEMBL1276369 | 0.82 | EGFR (0.40) | SCN9APAK1CCNT1CCNKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3205647-B1 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2019-02-07 | — | — | US | disclosed |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3205647-A2 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Memorial Sloan-Kettering Cancer Center (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2017-06-15 | — | — | US | disclosed |
| US-9567318-B2 | Substituted pyrimidine compounds and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2011022440-A9 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2467142-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | Memorial Sloan-Kettering Cancer Center (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022440-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | HRH4 4460/4885LRRK2 868/4885NOX1 4585/4885 |
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | HRH4 4460/4885LRRK2 868/4885NOX1 4585/4885 |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | HRH4 4460/4885LRRK2 868/4885NOX1 4585/4885 |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | HRH4 4460/4885LRRK2 868/4885NOX1 4585/4885 |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | HRH4 4460/4885LRRK2 868/4885NOX1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.